At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Catherine Kelly (Mater Misericordiae University Hospital, Dublin, Ireland) reviews the medical and social implications of BRCA gene mutation testing.
Women with a deleterious BRCA gene mutation can be offered various management options, including prophylactic surgery and chemoprevention, to reduce the risk of breast cancer development. It is important for clinicians to understand and respond to the patient’s subjective experience during the clinical management process.
This programme is supported by BioMarin Pharmaceutical.
